Frequency Distribution of CYP2C9 and VKORC1 Mutations among Bulgarian Patients and their Importance for Anticoagulant Therapy

被引:0
作者
Velizarova, Milena [1 ,2 ]
Abedinov, Philip [3 ]
Svinarov, Dobrin [1 ,2 ]
Nikolov, Valentin [4 ]
Hristova, Julieta [1 ,2 ]
机构
[1] Med Univ Sofia, Fac Med, Dept Clin Lab, Sofia, Bulgaria
[2] Alexander Univ Hosp, Sofia, Bulgaria
[3] St Ekaterina Univ Hosp, Sofia, Bulgaria
[4] SGP Bio Dynam Ltd, Sofia, Bulgaria
关键词
CYP2C9; oral anticoagulants; pharmacogenetics; VKORC1; GENETIC POLYMORPHISMS; PRESCRIBING ERRORS; WARFARIN; PREVALENCE; REQUIREMENT; GENOTYPE;
D O I
10.7754/Clin.Lab.2022.220213
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Genetic polymorphisms of CYP2C9 and VKORC1 play a major role in pharmacokinetics and pharmacodynamics of coumarin anticoagulants. The purpose of our study was to assess the relative frequency of the above mutations in Bulgarian population in order to predict bleeding tendencies and precisely manage the anticoagulant therapy during the postoperative period after cardiac surgery with extracorporeal circulation. Methods: Genomic DNA samples from 200 Bulgarian patients subjected to cardiac surgery with extracorporeal circulation were analyzed for VKORC1 1639G>A and CYP2C9*2&*3 polymorphisms by real-time polymerase chain reaction (PCR), then allele frequencies of various genotypes were calculated by Hardy-Weinberg Equilibrium. Results: Median patients' age was 63.9 +/- 10.8 years; 66.5% were male. Median BMI was 28.6 +/- 5.4 kg/m 2 . Genotype distribution for CYP2C9 was *1/*1 - 51%, *1/*2 - 21%, *1/*3 - 13.5%, *2/*3 - 4%, *3/*3 - 2%, and *2/*2 1.5%. The calculated frequency of CYP2C9*1 allele was 74.25%, CYP2C9*2 allele was 13%, and CYP2C9*3 allele was 12.75%, and all allelic frequencies were in Hardy-Weinberg equilibrium (p-value = 0.358). The major VKORC1 genotype was G/A - 47%, followed by G/G - 35.5% and A/A - 17.5%). Based on Hardy-Weinberg Equilibrium, there was no significant difference between observed and expected frequencies (X - -3.779), presumably as a result of the homogeneity in the population. Conclusions: Analysis of the data obtained in the course of the study suggested that identification of homozygous carriers of VKORC1-1639 G>A (rs9923231) in Bulgarians may be useful in developing recommendations for personalized therapy. On the contrary, homozygous carriers of CYP2C9*2 or *3, included only 4.5% of the studied patients, thus indicating that this group would benefit less from dosing algorithms. Our results demonstrated good agreement with the results obtained in other studies conducted in the Caucasian population.
引用
收藏
页码:2527 / 2532
页数:6
相关论文
共 50 条
  • [41] VKORC1 and CYP2C9 Genotypes are Predictors of Warfarin-Related Outcomes in Children
    Shaw, Kaitlyn
    Amstutz, Ursula
    Hildebrand, Claudette
    Rassekh, S. Rod
    Hosking, Martin
    Neville, Kathleen
    Leeder, J. Steven
    Hayden, Michael R.
    Ross, Colin J.
    Carleton, Bruce C.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (06) : 1055 - 1062
  • [42] Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe
    Buzoianu, Anca D.
    Trifa, Adrian P.
    Muresanu, Dafin F.
    Crisan, Sorin
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2012, 16 (12) : 2919 - 2924
  • [43] Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients
    Kumar, Dhakchinamoorthi Krishna
    Madhan, Sivalingam
    Balachander, Jayaramen
    Chandran, B. V. Sai
    Thamijarassy, Bascarne
    Adithan, Chandrasekaran
    THROMBOSIS RESEARCH, 2013, 131 (04) : 363 - 367
  • [44] Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients
    Taisei Mushiroda
    Yozo Ohnishi
    Susumu Saito
    Atsushi Takahashi
    Yuka Kikuchi
    Shigeru Saito
    Hideki Shimomura
    Yasuhiko Wanibuchi
    Takao Suzuki
    Naoyuki Kamatani
    Yusuke Nakamura
    Journal of Human Genetics, 2006, 51 : 249 - 253
  • [45] Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy
    Shaw, Kaitlyn
    Amstutz, Ursula
    Kim, Richard B.
    Lesko, Lawrence J.
    Turgeon, Jacques
    Michaud, Veronique
    Hwang, Soomi
    Ito, Shinya
    Ross, Colin
    Carleton, Bruce C.
    THERAPEUTIC DRUG MONITORING, 2015, 37 (04) : 428 - 436
  • [46] PREVALENCE OF COMBINATORIAL CYP2C9 AND VKORC1 GENOTYPES IN PUERTO RICANS: IMPLICATIONS FOR WARFARIN MANAGEMENT IN HISPANICS
    Duconge, Jorge
    Cadilla, Carmen L.
    Windemuth, Andreas
    Kocherla, Mohan
    Gorowski, Krystyna
    Seip, Richard L.
    Bogaard, Kali
    Renta, Jessica Y.
    Piovanetti, Paola
    D'Agostino, Darrin
    Santiago-Borrero, Pedro J.
    Ruano, Gualberto
    ETHNICITY & DISEASE, 2009, 19 (04) : 390 - 395
  • [47] Prediction of the impact of CYP2C9 and VKORC1 genotypes on warfarin-sorafenib interactions in whites and Asians
    Asari, Kazuhiko
    Takahashi, Harumi
    PHARMACOGENOMICS, 2020, 21 (12) : 853 - 862
  • [48] Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients
    Zhang, Suli
    Zhao, Mingzhe
    Zhong, Shilong
    Niu, Jiamin
    Zhou, Lijuan
    Zhu, Bin
    Su, Haili
    Cao, Wei
    Xing, Qinghe
    Yan, Hongli
    Han, Xia
    Fu, Qihua
    Li, Qiang
    Chen, Luan
    Yang, Fan
    Zhang, Na
    Wu, Hao
    He, Lin
    Qin, Shengying
    PHARMACOGENETICS AND GENOMICS, 2024, 34 (04) : 105 - 116
  • [49] Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes
    Baranova, E. V.
    Verhoef, T. I.
    Ragia, G.
    le Cessie, S.
    Asselbergs, F. W.
    de Boer, A.
    Manolopoulos, V. G.
    Maitland-van der Zee, A. H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (03) : 465 - 472
  • [50] Effect of VKORC1 and CYP2C9 variants on dosage of oral anticoagulants in Chilean individuals
    Benavides, Felipe
    Grossman, Nicole
    Poggi, Helena
    Nieto, Elena
    Bertran, Antonio
    Araos, Daniel
    Vasquez, Marcos
    Ibarra, Ignaz
    Caceres, Felipe
    Espinoza, Karena
    Lagos, Marcel
    Repetto M, Gabriela
    REVISTA MEDICA DE CHILE, 2015, 143 (11) : 1369 - 1376